Bitcoin price today: gains to $120k, near record high on U.S. regulatory cheer
Director John W. Kozarich of Ligand Pharmaceuticals INC (NASDAQ:LGND) sold 934 shares of common stock on July 10, 2025, at a price of $125.0, totaling $116750. The transaction occurs as LGND trades near its 52-week high of $129.90, with the stock showing strong momentum, delivering a 24% return over the past year. According to InvestingPro analysis, the company currently appears fairly valued.
According to a Form 4 filing with the Securities and Exchange Commission, the transaction was executed pursuant to a pre-arranged trading plan under Rule 10b5-1, which was adopted on March 07, 2025. Following the sale, Kozarich directly owns 46456 shares of Ligand Pharmaceuticals INC, which represents a stake in a company that maintains strong financial health with a current ratio of 5.27. InvestingPro subscribers have access to 10 additional key insights about LGND’s financial position and growth prospects.
In other recent news, Ligand Pharmaceuticals reported a strong performance in Q1 2025, surpassing both earnings per share (EPS) and revenue forecasts. The company achieved an adjusted EPS of $1.33, exceeding the expected $1.22, and recorded a total revenue of $45 million, which was above the projected $37.92 million. Ligand’s revenue rose by 46% year-over-year, driven by a significant increase in royalty revenue. Additionally, Ligand completed a merger involving its subsidiary LNHC, Inc. and Channel Therapeutics Corporation’s subsidiary, forming Pelthos Therapeutics Inc., which will focus on launching ZELSUVMI, a treatment for molluscum contagiosum. Concurrent with the merger, Pelthos raised $50.1 million in equity capital. Ligand is entitled to a 13% royalty on worldwide sales of ZELSUVMI and has received a $5 million milestone payment following the product’s commercial launch. Analyst firms such as RBC Capital Markets and Craig Hallum have been closely following these developments, with RBC Capital Markets noting the increasing number of special situations in the biotech sector. Ligand has reaffirmed its full-year guidance, projecting continued growth in royalty revenue and adjusted EPS for 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.